Related Experiment Video
Updated: Jul 4, 2025

10:21
Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells
Published on: January 5, 2018
13.2K
Correction: Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells
Yunfei Liao1,2, Lulu Chen1, Yong Feng2,3
1Department of Endocrinology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Oncotarget
|February 8, 2024
Summary
No abstract available in PubMed .

